NanOlogy Publishes Research Articles on the Immunomodulatory Effects of its Large Surface Area Microparticle Investigational Drugs
NanOlogy Publishes Research Articles on the Immunomodulatory Effects of its Large Surface Area Microparticle Investigational Drugs FORT WORTH (February 14, 2024) — NanOlogy LLC, a clinical-st ...
NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC
NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC Interim response and peripheral immunomodulation data from its Phase 2 clinical trial of IT LSAM-PTX in stage 3/4 lung ca ...
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the IASLC North America Conference on Lung Cancer
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the IASLC North America Conference on Lung Cancer FORT WORTH (November 20, 2023) — NanOlogy LLC, a clinical-stage oncology ...
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the 38th SITC Annual Meeting
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the 38th SITC Annual Meeting FORT WORTH (October 23, 2023) — NanOlogy LLC, a clinical-stage oncology company, announced to ...
Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer
Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer Research article published in Pancreas ...
NanOlogy Announces Two Abstracts Have Been Accepted for Presentation at AACR Special Conference in Cancer Research: Pancreatic Cancer
NanOlogy Announces Two Abstracts Have Been Accepted for Presentation at AACR Special Conference in Cancer Research: Pancreatic Cancer FORT WORTH (September 12, 2023) — NanOlogy LLC, a clinica ...
NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs
NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs FORT WORTH, Texas--NanOlogy LLC, a clinical-stage oncolog ...
NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer
NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer Covers intratumoral delivery of certain LSAM investigational ...
NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts
NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts FORT WORTH (December 20, 2022) — NanOlogy LLC, a clinical-stage interventional oncology d ...
NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer
NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer FORT WORTH (November 11, 2022) — NanOlogy LLC, a clinical-stage inte ...
NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX
NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX FORT WORTH, Texas--September 20, 2022--NanOlogy LLC, a clinical-stage interventional oncology drug c ...
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer FORT WORTH (August 1, 2022) — Na ...
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer FORT WORTH, Texas--NanOlogy LLC, a clini ...
Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care
Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care Presentation of Single-Site Clinical Trial Data Analysis at ACG 2021 ...
Additional Data Presented at DDW® 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac® for Mucinous Cystic Neoplasms of the Pancreas
Additional Data Presented at DDW® 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac® for Mucinous Cystic Neoplasms of the Pancreas FORT WORTH, Texas--(BUSINESS WIRE)--NanOlogy, LLC, a clinica ...
NanOlogy Announces First Patient Enrollment in Lung Cancer Clinical Trial
NanOlogy Announces First Patient Enrollment in Lung Cancer Clinical Trial FT. WORTH, (April 27, 2021) — NanOlogy, LLC, a clinical-stage interventional oncology drug therapy company, ...
NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial
NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial FT. WORTH, (March 9, 2021) — NanOlogy, LLC, a clinical-stage oncology company, today announced that enrollment has been complete ...
NanOlogy Presents Results of SOR007 (Topical Submicron Particle Paclitaxel) Phase 1/2 Clinical Trial in the Treatment of Cutaneous Metastases at 2020 SABCS®
Download PDF NanOlogy Presents Results of SOR007 (Topical Submicron Particle Paclitaxel) Phase 1/2 Clinical Trial in the Treatment of Cutaneous Metastases at 2020 SABCS® FT. WORTH, ...
NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac® for Intratumoral Treatment of Prostate Cancer
Download PDF NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac® for Intratumoral Treatment of Prostate Cancer Follows completion of a first-in-human dose-rising study ...
NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac® in Lung Cancer
Download PDF NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac® in Lung Cancer First-in-human clinical trial of intratu ...